Promising results for Roche’s ALINA Trial for Alecensa

Viewpoint
Read 1 min

The ALINA Trial for the lung cancer drug Alecensa by Roche went promising.
Alecensa is already in use for advanced stages of lung cancer and now shows as well positive results in early-stage cancer tests. ROG SE was already up pre-market, and the spot (CHF 261.45) still offers decent upside potential.

That keeping in mind and considering the current low volatility environment a Capped Outperformance Certificate with a Cap equaling the Vontobel Price Target (CHF 336) could be an ideal Product to participate with a leverage of 1.89 on Roche’s upside move.
Source: Vontobel Research September 2023

Underlying at a glance (Source: Vontobel, 01/09/2023)

  • Ticker: ROG SE
  • Description: Roche Holding AG Genussschein
  • Vontobel Rating: Buy
  • Price Target: CHF 336


Historical prizes normalized to 100 (Source: Vontobel, 01/09/2023)

Historic-deritrade-Capped-Outperformance-Certificate-Roche_en

Would you like to learn more about Outperformance Certificates? 
Reach out to our deritrade team today. We are here to guide you every step of the way, helping you achieve your financial goals with confidence and efficiency.   

Explore related topics:
Viewpoint
Most viewed:
The U.S. elections - potential opportunities for investment portfoliosNew Pricing Form on deritradeHow to invest in Barrier Reverse Convertibles
Up next:
Credit Linked Notes (CLNs) on iTraxx Indices